Reframing TRT and Prostate Cancer
Testosterone replacement therapy (TRT) for patients with a history of prostate cancer is more nuanced than once believed. While it isn’t for all men, new data suggests it can be an option when certain conditions are met.
Testosterone replacement therapy (TRT) and prostate cancer in the same context have held a lot of tension in the past. More recent data, accumulated over the years, shows that TRT, when used carefully in appropriately selected men, does not appear to increase the risk of prostate cancer recurrence or progression in the way once feared.
TRT is context-dependent rather than categorically dangerous, and hinges on who the patient is, what kind of cancer they had, how it was treated, and whether there is any sign or concern for cancer recurrence. Conversations centered on uncertainty and the trade-offs of TRT are paramount, and the patient should be closely monitored once TRT is started.
For example, a man with low-risk disease in remission with stable PSA levels and significant hypogonadal symptoms is not the same clinical scenario as someone with high-risk or advanced disease. Lumping them together under a single rule doesn’t hold up anymore. In fact, the British Society for Sexual Medicine, American Urological Association, and European Association of Urology now support the cautious use of TRT in specific groups of men with a history of prostate cancer.¹
What the Evidence Shows
In men without prostate cancer, data is the least controversial. Across multiple studies, TRT doesn’t seem to increase prostate cancer incidence in a meaningful way.¹
For men on active surveillance (low-risk disease that hasn’t been treated yet), there doesn’t seem to be an increased rate of cancer progression. Overall, there is encouraging data.¹
After radical prostatectomy, some studies suggest lower cancer recurrence rates in men on TRT, and quality-of-life improvements with regard to Low-T are straightforward: increased libido, improved energy, and overall symptom relief. After radiotherapy, TRT also appears to be generally safe.² A responsible tactic in select men after prostate cancer treatment is waiting until PSA reaches a stable nadir before starting TRT and then following closely.
The benefits of TRT are still there for men with a prostate cancer history, but the biology is a little different. Timing and monitoring matter more in the context of cancer history, aggressiveness, and treatment.
Who Gets TRT?
TRT is neither universally safe nor unsafe in men with a history of prostate cancer, and the decision is very selective. For high-risk patients, the data is limited, and caution is still exercised.
The most appropriate candidates are symptomatic hypogonadal men who are already disease-free after treatment for low- or intermediate-risk prostate cancer. In high-risk disease or advanced and metastatic cases, TRT remains outside standard recommendations or is only considered in very specific circumstances. Urology, oncology, and endocrinology perspectives and input are collectively important because the decision spans multiple risk domains – prostate function, cancer progression, and hormone regulation are influenced simultaneously.
Fully informed patient consent actually makes sure patients understand that long-term oncologic risk is not absolute. And once TRT is started, monitoring is not optional. Regular PSA testing, testosterone levels, MRI, or repeat biopsies may be part of the protocol.
Improvements in energy, mood, libido, and erectile function are why treatment is pursued in the first place. Part of the conversation, then, is about oncologic safety as well as survivorship quality and how patients are actually functioning day to day.
If you are experiencing symptoms of Low-T or hypogonadism, talk to the team at Georgia Urology. Our doctors are well-versed in both prostate-related conditions and TRT, and can help guide you to the best solutions for your current circumstances.
References:
-
Edison, M. A., Kirby, M., & Hackett, G. I. (2026). Testosterone Replacement Therapy in Hypogonadal Men with a Prostate Cancer Diagnosis: A British Society for Sexual Medicine Consensus Statement. The World Journal of Men’s Health, 44(1), 5–22. https://doi.org/10.5534/wjmh.250086.
-
Edison, M. A., Kirby, M., & Hackett, G. I. (2026). Testosterone Replacement Therapy in Hypogonadal Men with a Prostate Cancer Diagnosis: A British Society for Sexual Medicine Consensus Statement. The World Journal of Men’s Health, 44(1), 5–22. https://doi.org/10.5534/wjmh.250086.
